

PRECONFERENCE WORKSHOP
SUNDAY 14TH NOVEMBER

14.25-18.10 (supported by an unrestricted grant from the American Autoimmune Related Diseases Associated Inc. (AARDA))

Update on the International Classification Criteria for the
Antiphospholipid Syndrome

INTRODUCTION	S. Krilis 14.25-14.30
14.30-14.40 Ricard Cervera 14.40-14.50 Discussion	CARDIAC MANIFESTATIONS Ricard Cervera , Yehuda Shoenfeld, Ricardo Forastiero
14.50-15.00 Ware Branch 15.00-15.10 Discussion	OBSTETRIC MANIFESTATIONS, PREGNANCY AND MORBIDITY CRITERIA (A) PRE-ECLAMPSIA (B) HELP SYNDROME (C) INTRAUTERINE GROWTH RETARDATION Ware Branch , Roger Levy, Ron Derksen
15.10-15.20 Robin Brey 15.20-15.30 Discussion	NEUROLOGICAL MANIFESTATIONS, STROKE (A) MIGRAINE (B) MULTIPLE SCLEROSIS-LIKE ILLNESS (C) TRANSVERSE MYELOPATHY (D) COGNITIVE DYSFUNCTION (E) SEIZURES Robin Brey , Joab Chapman, Jacob Rand, S. Levine
15.30-15.40 Yehuda Shoenfeld 15.40-15.50 Discussion	CUTANEOUS MANIFESTATIONS (A) LIVEDO RETICULARIS (B) CUTANEOUS ULCERS/VASCULITIS Yehuda Shoenfeld , Ricard Cervera
15.50-16.00 PierLuigi Meroni 16.00-16.10 Discussion	RENAL MANIFESTATIONS PierLuigi Meroni , Panayiotis Vlachoyiannopoulos
16.10-16.20 Takao Koike 16.20-16.30 Discussion	THROMBOCYTOPENIA Takao Koike , Pierre Youinou, Benjamin Brenner

SUNDAY 14TH NOVEMBER

16.30-16.40 Angela Tincani 16.40-16.50 Guido Reber 16.50-17.00 Discussion	DIAGNOSTIC TESTS (A) CURRENT STATUS OF IGA (B) ANTI-BETA2-GLYCOPROTEIN I Angela Tincani and Guido Reber , Robert Roubey, E Nigel Harris, Silvia Pierangeli
17.00-17.10 Flip de Groot 17.10-17.20 Ron Derksen 17.20-17.30 Discussion	LUPUS ANTICOAGULANT/BETA2-GPI/PROTHROMBIN/OTHER PROTEIN SPECIFICITIES Flip de Groot , Ron Derksen , Tom Exner, Victoria Regnault, P. de Moerloose
17.30-17.40 Takao Koike 17.40-17.50 Discussion	ANTIPROTHROMBIN ANTIBODIES Takao Koike , Monica Galli, Joyce Rauch, T. Atsumi
17.50-18.00 Michael Lockshin 18.00-18.10 Discussion	Summary of how well the criteria work so far and what are the problems Michael Lockshin

IMMUNE MEDIATED MECHANISMS OF THROMBOSIS
CHAIRPERSONS – SA KRILIS, T. KOIKE

- 8.25 Welcome Speech
S.A. Krilis, Australia
- 8.30 B CELL BIOLOGY, APOPTOSIS, AND AUTOANTIBODIES
TO PHOSPHOLIPIDS
M. Cook, Australia
- 8.55 THE IMPACT OF THE INFLAMMATORY RESPONSE ON
COAGULATION
C. Esmon, United States
- 9.20 INFLAMMATORY RESPONSE AND THE ENDOTHELIUM
PL Meroni, Italy

BETA 2-GLYCOPROTEIN I

- 9.45 BETA 2 GLYCOPROTEIN I -FUNCTION IN HEALTH AND
DISEASE
S. Krilis, S. Miyakis, Australia
- 10.10 B₂-GLYCOPROTEIN I: ANTIPHOSPHOLIPID SYNDROME
AND T-CELL REACTIVITY
M. Kuwana, Japan
- 10.35 **COFFEE BREAK**

ANTIPHOSPHOLIPID SYNDROME
CHAIRPERSONS – EN HARRIS, R. ROUBEY

- 10.50 PRIMARY, SECONDARY, CATASTROPHIC ANTIPHOSPHOLIPID
SYNDROME: IS THERE A DIFFERENCE?
EN Harris, SS Pierangeli, United States
- 11.10 PRIMARY ANTIPHOSPHOLIPID ANTIBODY SYNDROME AS A
MODEL OF B CELL-INDUCED AUTOIMMUNE DISEASE
P. Youinou, France

- 11.30 CELL SIGNALLING PATHWAYS UNDERLYING PATHOGENIC AUTOIMMUNITY
M. Zouali, France
- 11.50 ANTI-PHOSPHOLIPID ANTIBODIES AND APOPTOSIS
J. Rauch, R. Subang, JS Levine, Canada
- 12.10 ANTIBODY-MEDIATED INTERFERENCE WITH ANNEXINS IN THE ANTIPHOSPHOLIPID SYNDROME
J. Rand, X-X Yu, United States
- 12.30 MECHANISMS OF AUTOANTIBODY- INDUCED MONOCYTE TISSUE FACTOR EXPRESSION
R. Roubey, AS Wolberg, United States

12.50 LUNCH & POSTER VIEWING

CHAIRPERSONS – J. MCINTYRE, SS PIERANGELI, S. LEVINE

- 13.50 EFFECTS OF FLUVASTATIN ON UPREGULATION OF TISSUE FACTOR BY ANTIPHOSPHOLIPID ANTIBODIES ON ENDOTHELIAL CELLS
SS Pierangeli, DE Ferrara, R. Swerlick, M. Vega-Ostertag, K. Casper, PL Meroni, EN Harris
- 14.02 CONCORDANCE AMONG APL ASSAYS IN ISCHEMIC STROKE: A SUBSET ANALYSIS OF THE WARSS/APASS COLLABORATION
SR Levine, RL Brey, BC Tilley, JLT Thompson, RL Sacco, PA Padilla, E Du, JP Mohr, & The APASS Investigators, United States/Italy
- 14.14 COMPLEMENT C5 ACTIVATION MEDIATES ANTIPHOSPHOLIPID-INDUCED THROMBOSIS
SS Pierangeli, ME Vega-Ostertag, G. Giradi, X. Liu, JE Salmon, United States
- 14.26 ANTIPHOSPHOLIPID-INDUCED THROMBOSIS IS MEDIATED BY GPIIB/IIIA IN PLATELETS IN AN IN VIVO MOUSE MODEL
M. Vega-Ostetag, FL Pianciola, A. Liu, V. Henderson, EN Harris, SS Pierangeli, United States

- 14.38 EFFECT OF BETA 2-GLYCOPROTEIN I NULL MUTATION ON REPRODUCTIVE OUTCOME AND ANTIPHOSPHOLIPID ANTIBODY-MEDIATED PREGNANCY PATHOLOGY IN MICE
T. Shi, S. Robertson, C. Roberts, D. Bjeiring, K. Pensa, Y. Sheng, S. Krilis, Australia
- 14.50 ANTI-BETA2GLYCOPROTEIN I ANTIBODIES POTENTIATE THE INHIBITORY EFFECTS OF BETA2GLYCOPROTEIN I ON THE ACTIVATION OF FXI BY FIIa: EFFECTS OF CLIPPED BETA2GLYCOPROTEIN I
Q. Yang, T. Shi, C. Bester, B. Giannakopoulos, S. Krilis, Australia
- 15.02 HUMAN MONOCLONAL IGG ANTICARDIOLIPIN ANTIBODIES INDUCE NITRIC OXIDE SYNTHASE EXPRESSION
J. Delgado Alves, BR Clapp, R. Stidwill, PP Chen, AD Hingorani, M Singer, DA Isenberg, United States
- 15.14 BETA2-GLYCOPROTEIN I BINDS FXI & INHIBITS ITS ACTIVATION BY THROMBIN AND FXIIa: LOSS OF INHIBITION BY CLIPPED B2-GPI
T. Shi, C. Bester, Q. Yang, B. Giannakopoulos, GM Iverson, JC Qi, KA Cockerill, MD Linnik, P. Konecny, S. Krilis, Australia/ United States
- 15.26 ANTIPHOSPHOLIPID ANTIBODIES DECREASE PLAQUE FORMATION IN ATHEROSCLEROSIS-PRONE MICE
M. Monestier, D. Nicolo, S-A Kang, United States
- 15.38 ANTIPHOSPHOLIPID SYNDROME NEPHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
MG Tektonidou, F. Sotsiou, L. Nakopoulou, PG Vlachoyiannopoulos, HM Moutsopoulos, Greece
- 15.50 RITUXIMAB REDUCES ANTIPHOSPHOLIPID ANTIBODY TITERS & IMPROVES HYPERCOAGULABLE STATE WITHOUT RECURRENT THROMBOSES: 2-YEARS FOLLOW UP
M. Yamazaki, Y. Kawashima, A. Asakura, S. Nakao, Japan

16.02 THE ANTIPHOSPHOLIPID SYNDROME: IMMUNOLOGICAL AND CLINICAL ASPECTS
TM Reshetnyak, EN Alexandrova, IB Shtivelband, LV Kondrateva, AA Novikov, LA Kalashnikova, TA Lisitsyna, IE Shirokova, ZS Alekberova, EL Nassonov, Russia

16.14 ANTIPHOSPHOLIPID ANTIBODIES FOLLOWING VACCINATION WITH RECOMBINANT HEPATITIS B VACCINE
B. Bozic, T. Avcin, J. Martinuc, M. Kuhar, S. Cucnik, M. Zupancic, T. Kveder, B. Rozman Slovenia

16.26 COFFEE BREAK

CHAIRPERSONS – Y. SHOENFELD, P. VLACHOYIANNOPOULOS

16.56 HEAT SHOCK PROTEIN-60 REACTIVITY IS ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES IN VASCULITIS-RELATED AUTOIMMUNE DISEASES
P. Youinou, Y. Renaudinaeu, C. Dugué, J. Arvieux, R. Perrault, S. Krilis, France/Australia

17.08 HEAT SHOCK PROTEIN REACTIVITY IS ASSOCIATED WITH ANTIPHOSPHOLIPID ANTIBODIES IN VASCULITIS-RELATED AUTOIMMUNE DISEASE
P. Youinou, C. Dugué, JC Piette, D. Mottier, L. Guillevin, C. Jamin, France

17.20 T LYMPHOCYTE SUBSETS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME
PRJ Ames, C. Tommasino, G. Fossati, LR Lopez, E. Matsuura, A. Margarita, G. Scenna, V. Brancaccio, Italy/United States/Japan/United Kingdom

17.32 THE INFECTIOUS ETIOLOGY OF APS: NOVEL CROSS REACTIVE EPITOPES ON YEASTS, BACTERIA AND VIRUSES
Y. Shoenfeld, M. Blank, I. Krause, R. Cervera, J. Font, M. Torsten, Israel

17.44 BOTH C4A & C4B NULL ALLELES ARE ASSOCIATED WITH APLIN CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
BL Myones, KAB Marzan, JM Moulds, United States

17.56 A STUDY OF ANTICARDIOLIPIN ANTIBODIES IN ECLAMPSIA
EG Dachlan, A. Sulistyono, Indonesia

PREGNANCY AND ANTIPHOSPHOLIPID ANTIBODIES
CHAIRPERSONS – E. BENSON, RHWM DERKSON

- 8.30 GROWTH AND FUNCTION OF THE NORMAL HUMAN PLACENTA
N. Gude, Australia
- 8.55 MATERNAL HEMOSTASIS IN THE NORMAL PREGNANCY
B. Brenner, Israel
- 9.20 ANTIPHOSPHOLIPID ANTIBODIES AND FETAL COMPROMISE
DW Branch, United States
- 9.40 TREATING OF ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY
– A SYSTEMATIC REVIEW OF THERAPEUTIC TRIALS
MN Lassere, M. Empson Australia
- 10.00 IMMUNOLOGIC MANIPULATION FOR THE THREATENED FOETUS
E. Benson, Australia
- 10.20 COFFEE BREAK & POSTER VIEWING**

YOUNG INVESTIGATORS
CHAIRPERSONS – C. ESMON, B. BRENNER, M. ZOULI

- 10.50 BETA2-GLYCOPROTEIN I BINDS FXI BY ITS C-TERMINAL DOMAIN
& INHIBITS ITS ACTIVATION BY THROMBIN & FXIIa. PLASMIN
CLEAVAGE OF B2-GPI ABOLISHES ITS INHIBITION OF FXIIa
ACTIVATION OF FXI
*B. Giannakopoulos, C. Bester, T. Shi, GM Iverson, KA Cockerill, MD
Linnik, P. Konecny, S. Krilis, Australia/United States*
- 11.05 PATHOGENIC ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES
RECOGNIZE A POSITIVE CHARGED EPITOPE ON DOMAIN I
*HB de Laat, RHWM Derksen, RT Urbanus, GM Iverson, PhG de
Groot, Netherlands/United States*

- 11.20 ANTIPHOSPHOLIPID ANTIBODIES CAN REDUCE THE IN VITRO CLEAVAGE OF DOMAIN V OF BETA2-GLYCOPROTEIN I BY PLASMIN.
MJ Nash IJ Mackie H. Cohen SJ Machin, United Kingdom
- 11.35 INDUCTION OF ANTIPHOSPHOLIPID SYNDROME IN FACTOR V LEIDEN MICE
A. Katzav, CG Pick, M. Blank, Y. Shoenfeld, J.Chapman
- 11.50 IDENTIFICATION OF THE DOMAIN OF BETA2-GLYCOPROTEIN I INVOLVED IN BINDING TO LRP
M. Van Lummel, RHWM Derksen, BCH Lutters, E. Westein, PJ Lenting, PhG de Groot, Netherlands
- 12.05 IGG'S ISOLATED FROM PATIENT PLASMA OF APS PATIENTS BIND TO DOMAIN 1 OF BETA2-GLYCOPROTEIN 1
MTT Pennings HB de Laat RHWM Derksen GM Iverson PhG de Groot, Netherlands/United States
- 12.20 CLINICAL SIGNIFICANCE OF PHOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODY (APS/PT) BOUND ONLY TO HUMAN PROTHROMBIN IN APS PATIENTS WITH SEVERAL KINDS OF COLLAGEN DISEASE
Y. Kawashima, M. Yamazaki, H. Asakura, E. Morishita, S. Otake, Japan

12.35 LUNCH & POSTER VIEWING

CHAIRPERSONS – MD LOCKSHIN, PL MERONI, T. BRIGHTON

- 13.35 HOW MUCH WARFARIN IS ENOUGH IN APS-RELATED THROMBOSIS?
M. Lockshin, D. Erkan, United States
- 13.50 OPTIMAL THERAPY OF PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES AND THROMBOSIS: THE NEXT STEPS
M. Crowther, Canada
- 14.05 APLASA STUDY UPDATE: PRIMARY THROMBOSIS PREVENTION IN ASYMPTOMATIC APL (+) PATIENTS WITH ASPIRIN (ASA)
D. Erkan, L. Sammaritano, R. Levy, MJ Harrison, M. Peterson, Y. Yazici, MD Lockshin, United States/Brazil

- 14.17 RELATIVE RISK OF BLEEDING AND RETHROMBOSIS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME AT A TARGET INR OF 2-3. A 9 YEAR COMPARATIVE STUDY WITH INHERITED THROMBOPHILIA AND MITRAL VALVE REPLACEMENT PATIENTS.
PRJ Ames, A. Ciampa, M. Margaglione, A. Margarita, L. Iannaccone, G. Scenna, V. Brancaccio, United Kingdom/Italy
- 14.29 THE ANTIPHOSPHOLIPID SYNDROME COLLABORATIVE REGISTRY: INITIAL DESCRIPTION OF THE STUDY COHORT
RAS Roubey, G. Buxton, The APSCORE Investigators, United States
- 14.41 KALLIKREIN IS ABLE TO SPECIFICALLY CLEAVE BETA2-GLYCOPROTEIN I IN DOMAIN V
MJ Nash, IJ Mackie, SJ Machin, United Kingdom
- 14.53 IN-VITRO STUDY OF THE EFFECT OF HEPARINS ON TROPHOBLAST PROLIFERATION
C. McLintock, L. Chamley, A. Moore, P. Stone, New Zealand
- 15.05 BETA 2-GLYCOPROTEIN I DEPENDENT LUPUS ANTICOAGULANT HIGHLY CORRELATES WITH THROMBOSIS IN THE ANTIPHOSPHOLIPID SYNDROME
HB de Laet, RHWM Derksen, RT Urbanus, M. Roest, PhG de Groot, Netherlands
- 15.17 P38 MITOGEN ACTIVATED PROTEIN KINASE IS INVOLVED IN UPREGULATION OF TISSUE FACTOR IN ENDOTHELIAL CELLS BY ANTIPHOSPHOLIPID ANTIBODIES
ME Vega-Ostertag, V. Henderson, EN Harris, SS Pierangeli, United States
- 15.29 THE EFFICACY AND SPECIFICITY OF ANTI-ANTI- BETA-2GPI-IVIG FRACTION IN-VITRO AND IN AN ANIMAL MODEL.
Y. Shoenfeld, M. Blank, L. Ashkenazi, I. Nur, L. Bar, Israel
- 15.41 FLUVASTATIN INCREASES THE EXPRESSION OF ADHESION MOLECULES, MCP-1 AND TISSUE FACTOR IN HUVEC STIMULATED BY ANTIPHOSPHOLIPID ANTIBODIES
G. Reber, S. Dunoyer-Geindre, RJ Fish, N. Satta, EKO Kruithof, P. de Moerloose, Switzerland

CHAIRPERSONS- J. RAUCH, DW BRANCH, M-C BOFFA

- 15.53 ARE ENDOTHELIAL MARKERS ASSOCIATED WITH NEW THROMBOSIS?
C. Neville, S. Solymoss, J. Rauch, J. Kassis, L. Joseph, P. Belisle, E. Chang, R. Subang, M. Le Comte, PR Fortin, Canada
- 16.05 COFFEE BREAK**
- 16.25 PHOSPHATIDYLSERINE DEPENDENT ANTIPROTHROMBIN ANTIBODIES ARE NOT USEFUL FOR IDENTIFICATION WITH A HIGH RISK OF PATIENTS SUFFERING FROM RECURRENT MISCARRIAGES
MS Sugiura-Ogasawara, TA Atsumi, KK Katano, YO Ozaki, TN Nakanishi, TK Koike, KS Suzumori, Japan
- 16.37 THROMBOTIC AND VASCULAR EVENTS IN BABIES BORN TO MOTHERS WITH APS OR APLA
M CBoffa, E. Lachassinne, MH Aourousseau, M. Uzan, O. Fain, R. Rai, S. Sangle, T. Avcin, D. Farge, P. Douart, JC Piette, L. Regan, GRV Hughes, France/UnitedKingdom
- 16.49 IGG ANTICARDIOLIPIN ANTIBODY PROFILE ON SEVERE PREECLAMPSIA
A. Sulistyono, EG Dachlan, Indonesia
- 17.01 ARE ANTIPHOSPHOLIPID ANTIBODIES CONCENTRATED IN FOLLICULAR FLUID?
LW Chamley, AM Moore, PR Stone, New Zealand
- 17.13 ANTIPHOSPHOLIPID ANTIBODIES IN THE FOLLICULAR FLUID AND IVF OUTCOME
LW Chamley, K. Buckingham, PR Stone, New Zealand
- 17.25 ANTIPHOSPHOLIPID ANTIBODIES AND THROMBOPHILIA IN WOMEN WITH RECURRENT ABORTION AND FETAL LOSS. OUTCOME OF THERAPY WITH HEPARIN OR LMWH IN COMBINATION WITH ASPIRIN
KLT Tambunan, EW Wijono, NK Kampono, EJS Suryana,

TUESDAY NOVEMBER 16TH 2004

- 17.37 ANTIBODIES TO TFPI IN WOMEN WITH PREGNANCY
MORBIDITY OR IMPLANTATION FAILURES
RR Forastiero, ME Martinuzzo, ML Iglesias Varela, YP
Adamczuk, GJ Broze, Argentina/United States
- 17.49 ANTIPHOSPHOLIPID ANTIBODIES AND
CEREBROVASCULAR ACCIDENTS IN PATIENTS UNDER
50
B. Owlia, Z. Dehghani, F. Fallah, Iran
- 18.01 ATHEROSCLEROSIS IN PRIMARY ANTIPHOSPHOLIPID
SYNDROME
PRJ Ames, A. Margarita, L. Iannaccone, G. Scenna, United
Kingdom/Italy

PATHOPHYSIOLOGICAL MECHANISMS
CHAIRPERSONS – PhG de GROOT, J. RAND

- 8.30 PLATELET PHYSIOLOGY AND THROMBOSIS
RK Andrews, EE Gardiner, JF Arthur, MC Berndt, Australia
- 8.55 β 2-GLYCOPROTEIN I AND LDL-RECEPTOR FAMILY MEMBERS
PhG de Groot, M. van Lummel, M. Pennings, R. Urbanus, HB de Laat, PJ Lenting, RHWM Derksen, Netherlands
- 9.20 β 2-GLYCOPROTEIN I, ANTI- β 2-GLYCOPROTEIN I AND FIBRINOLYSIS
S. Yasuda, T. Atsumi, T. Koike, Japan
- 9.40 INTRACELLULAR SIGNALING TRIGGERED BY ANTIPHOSPHOLIPID ANTIBODIES IN PLATELETS AND ENDOTHELIAL CELLS: A PATHWAY TO TARGETED THERAPIES
SS Pierangeli, ME Vega-Ostertag, EN Harris, United States

CNS AND CARDIOVASCULAR MANIFESTATION OF APS

- 10.00 THE INTERFACE OF MULTIPLE SCLEROSIS AND ANTIPHOSPHOLIPID ANTIBODIES
J. Chapman, Israel
- 10.20 CONTROVERSIES IN THE ANTIPHOSPHOLIPID SYNDROME AND STROKE
PA Gatenby, Australia
- 10.40 MANAGEMENT OF THE NEUROLOGICAL MANIFESTATIONS OF APS – WHAT DO THE TRIALS TELL US?
RL Brey, United States
- 11.00 CORONARY AND VALVULAR SYNDROMES AND ANTIPHOSPHOLIPID ANTIBODIES
R. Cervera, Spain
- 11.20 PERIPHERAL VASCULAR DISEASE IN ANTIPHOSPHOLIPID SYNDROME
PG Vlachoyianopoulos, Greece

11.40 COFFEE BREAK

CHAIRPERSONS – R. CERVERA, J. DENBURG

- 12.00 ASSOCIATION OF SEVERE VALVULAR REGURGITATION WITH ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS
R. Cervera, J. Font, F. Pérez-Villa, M. Azqueta, C. Paré, G. Espinosa, JC Reverter, M. Ramos-Casals, M. Ingelmo, G. Sanz, Spain
- 12.12 RISK FACTORS FOR COGNITIVE DYSFUNCTION IN SLE: SAN ANTONIO LUPUS STUDY OF NEUROPSYCHIATRIC DISEASE
SL Holliday, AR Saklad, R. Garcia-Cavasos, M. Fischbach, PA Padilla, D. McGlasson, RL Brey, United States
- 12.24 ANTIPHOSPHOLIPID ANTIBODY (APL) IN SERUM AND CSF FROM PATIENTS WITH PSYCHOSIS
RS O'Brien, DK Sokol, DR Wagenknecht, TV Rao, JA McIntyre, United States
- 12.36 APS EXACERBATES AMYLOID DEPOSITION AS WELL AS MEMORY IMPAIRMENT IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE
A. Katzav, CG Pick, DM Michaelson, M. Blank, Y. Shoenfeld, J. Chapman, Israel
- 12.48 MECHANISMS OF NEURONAL DAMAGE IN SLE AND APLS: THERAPEUTIC IMPLICATIONS
JA Denburg, MM Sidor, MM Cyr, D. Ballock, L. Doering, H. Szechtman, B. Sakic, Canada
- 13.03 PHOSPHOLIPID ANTIBODIES AND COGNITIVE FUNCTION: PATTERNS AND PREDICTION
SD Denburg, JA Denburg, Canada

WEDNESDAY NOVEMBER 17TH 2004

**14.00-1600 HARBOUR CRUISE WITH LATE LUNCH
AND AUSTRALIAN WINES AND BEER
All Delegates and Accompanying persons**



**19.30-11.30 CONGRESS BANQUET
All Ticket Holders**



MEASUREMENT OF AUTOANTIBODIES IN APL, WHICH ONES?

CHAIRPERSONS – T. EXNER, R. LEVY

- 8.30 TESTS FOR LUPUS ANTICOAGULANT REVISITED
RHWM Derksen, PhG de Groot, Netherlands
- 8.55 ANTI- β 2-GLYCOPROTEIN I ANTIBODIES – WHEN AND
HOW SHOULD THEY BE MEASURED ?
G. Reber, P. de Moerloose, Switzerland
- 9.20 ANTIPROTHOMBIN ANTIBODIES – ARE THEY WORTH
ASSAYING ? –
T. Atsumi, O. Amengual, S. Yasuda, T. Koike, Japan
- 9.45 PHENOTYPING THE HAEMOSTATIC SYSTEM BY
THROMBOGRAPHY – PROSPECTS TO THE ESTIMATION
OF THE THROMBOTIC RISK
*V. Regnault, HC Hemker, D. Wahl, T. Lecompte,
France/Netherlands*

10.10 COFFEE BREAK

CHAIRPERSONS – A. TINCANI, J. MCINTYRE

- 10.30 DETECTION OF PROCOAGULANT PHOSPHOLIPID INTERFERING
IN TESTS FOR LUPUS ANTICOAGULANT
T. Exner, J. Low, Australia
- 10.45 MINIMAL REQUIREMENTS OF APL ELISAS
*A. Tincani, F. Allegri, G. Balestrieri, G. Reber, M. Sanmarco, PL
Meroni, MC Boffa, Italy/Switzerland/France*
- 11.00 CONSENSUS GUIDELINES FOR ANTICARDIOLIPIN ANTIBODY
TESTING
RCW Wong, Australia
- 11.20 ASSESSMENT OF THE ROLE OF ANTICARDIOLIPIN ANTIBODY
TEST IN DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME
EN Harris, SS Pierangeli, United States

11.35 AN ADAPTED ELISA METHOD FOR DIFFERENTIATING PATHOGENIC FROM NON-PATHOGENIC APL BY A β_2 -GLYCOPROTEIN I DEPENDENCY ANTI-CARDIOLIPIN ASSAY.
RA Levy, *E. de Meis, SS Pierangeli, Brazil/United States*

11.50 THE APPEARANCE AND DISAPPEARANCE OF APL AUTOANTIBODIES SUBSEQUENT TO OXIDATION – REDUCTION (REDOX) REACTIONS
JA McIntyre, *United States*

12.10 LIBMAN-SACKS ENDOCARDITIS ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME AND INFECTION
Y. Shoenfeld, *M. Blank, A. Shani, I. Goldberg, J. Kopilovic, MC Amigo, L. Magrini, Israel/Mexico/Italy*

12.30 LUNCH & POSTER VIEWING

CHAIRPERSONS – M. GALLI, SS PIERANGELI

13.30 ANTIPHOSPHOLIPID ANTIBODIES ARE A RISK FACTOR FOR MYOCARDIAL INFARCTION (BUT NOT ATHEROSCLEROSIS): HOPKINS LUPUS COHORT
M. Petri, *United States*

13.50 ANTIPHOSPHOLIPID ANTIBODIES AND THROMBOSIS: DO TEST PATTERNS IDENTIFY THE PATIENTS' RISK?
M. Galli, *Italy*

14.10 REAL WORLD EXPERIENCE WITH ANTIPHOSPHOLIPID ANTIBODIES(APL): HOW STABLE ARE APL OVER TIME?
W. Derksen, *D. Erkan, V. Kaplan, L. Sammaritano, SS Pierangeli, MD Lockshin, Netherlands/United States*

14.22 REAL WORLD EXPERIENCE WITH APL: COMPARISON BETWEEN APS AND ASYMPTOMATIC APL-POSITIVE PATIENTS
W. Derksen, *D. Erkan, V. Kaplan, L. Sammaritano, MD Lockshin, Netherlands/United States*

- 14.34 ROLES OF ADHESION MOLECULES IN THE DEVELOPMENT OF THROMBOSIS AND PREGNANT MORBIDITY IN ANTIPHOSPHOLIPID SYNDROME (APS): STUDIES USING APS MODEL MICE DEFICIENT OF ADHERENT MOLECULES
M. Yamazaki, Y. Kawashima, H. Asakura, S. Nakao, Japan
- 14.46 REPORT ON THE EUROPEAN COLLABORATIVE STUDY ON ANTIPHOSPHATIDYLETHANOLAMINE ANTIBODIES
M. Sanmarco, S. Gayet, MC Alessi, M. Audrain, B. Boneu, E. de Maistre, JC Gris, P. de Groot, E. Hachulla, I. Kontopoulou-Grivas, P. Sié, France/Netherlands/Greece (European Forum on aPL)
- 14.58 RELATIONSHIP BETWEEN ANTI-PROTEIN S (ANTI-PS) AND ANTIPHOSPHATIDYLETHANOLAMINE (APE) ANTIBODIES IN PATIENTS WITH CLINICAL FEATURES OF ANTIPHOSPHOLIPID SYNDROME (APS)
M. Sanmarco, N. Bardin, P. Roll, MC Alessi, France
- 15.10 THE PREVALENCE AND CLINICAL SIGNIFICANCE OF IGA ANTIPHOSPHOLIPID ANTIBODIES
YP Shen, AM Dyszkiewicz-Korpanty, R. Lee, J. Balani, EP Frenkel, R. Sarode, United States

15.22 COFFEE & POSTER VIEWING

CHAIRPERSONS – G. REBER, I. MACKIE

- 16.00 ASSOCIATION OF HIGH AVIDITY ANTI-BETA2GPI ANTIBODIES WITH THROMBOSIS IN PATIENTS WITH APS
B. Božič, S. Cucnik, T. Kveder, B. Rozman, Slovenia
- 16.12 EVALUATION OF TEN COMMERCIAL ASSAYS FOR THE QUANTITATION OF ANTI-B2GLYCOPROTEIN I ANTIBODIES. ON BEHALF OF THE STANDARDISATION GROUP OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
G. Reber, M. Sanmarco, A. Tincani, P. de Moerloose, MC Boffa, Switzerland/France
- 16.24 LABORATORY DIAGNOSIS OF LUPUS ANTICOAGULANT IN PATIENTS ON ORAL ANTICOAGULANT
M. Aboud, CM Ward, L. Coyle, Australia

- 16.36 ANTIPHOSPHOLIPID AND ANTINUCLEAR ANTIBODIES FOLLOWING INFLIXIMAB TREATMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS
F. Atzeni, P. Sarzi-Puttini, G. Randisi, MG Marrazza, M. Carrabba, F. Capsoni, Italy
- 16.48 PROLONGED BLEEDING TIME AND LUPUS ANTICOAGULANT: A SECOND PARADOX IN THE ANTIPHOSPHOLIPID SYNDROME
RT Urbanus, *HB de Laat, PhG de Groot, RHWM Derksen, Netherlands*
- 17.00 A PROTOTYPE COMMERCIAL ELISA FOR PROTEIN S ANTIBODIES
IJ Mackie, *HB de Laat, G. Purdy, M. Adam, B. Woodhams, RHWM Derksen, PhG de Groot, United Kingdom/Netherlands/France*
- 17.12 THROMBOGRAPHY ALLOWS RELIABLE STUDY OF THE PROTEIN C SYSTEM IN APS AND EVIDENCES A STRONG PHENOTYPIC HETEROGENEITY
D. Wahl, *V. Regnault, S. Béguin, E. de Maistre, P. Kaminsky, HC Hemker, T. Lecompte, France/Netherlands*
- 17.24 DOES SLE AFFECT THE OUTCOME IN CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME (CAPS)?
D. Erkan, *R. Asherson, R. Cervera, G. Espinosa, S. Bucciarelli, JA Gómez-Puerta, J. Font, United States/South Africa/Spain*
- 17.36 ASSESSMENT OF PLATELET FUNCTION UNDER FLOW CONDITION IN PATIENTS WITH SCLERODERMA AND ANTIPHOSPHOLIPID SYNDROME USING THE CONE AND PLATE(LET) ANALYZER
D. Varon, *Y. Levy, B. Shenkman, R. Pauzner, Y. Shoenfeld, N. Savion, Israel*
- 17.48 OBSTETRICAL APS: HEPARIN DOSING BASED ON PHARMACOKINETICS
MD Stephenson, *MHH Ensom, Canada*

MONDAY 15 JULY 2004 Posters 8.30am to 5.30pm

- [1] **Are Acquired Activated Protein C Resistance (APCR) and Hyperhomocysteinemia Associated with New Thrombosis?**
Canada
J. Kassis, C. Neville, S. Solymoss, E. Chang, J. Rauch, L. Joseph, P. Belisle, M. Le Comte, R. Subang, PR Fortin
- [2] **Two Adolescents with Neurological Abnormalities and Elevated Antiphospholipid Antibodies**
United States
A. Gedalia, H. Sinclair, S. Deputy, W. Wilson
- [3] **Elevated Levels Of Baff Correlate With Antiphospholipid Antibody Production In Systemic Lupus Erythematosus**
France
B. Bendaoud, Y. Penneç, A. Sarauç, Y. Renaudineau, C. Jamin, **P. Youinou**
- [4] **Prevalence of Antiphospholipid Antibodies in Rheumatoid Arthritis**
Israel/Italy
Y. Sherer, R. Gerli, R. Allegrucci, A. Giordano, B. Gilburd, G. Vaudo, S. Marchesi, G. Schiallaci, E. Mannarino, Y. Shoenfeld
- [5] **Thickened Carotid Artery Intima-Media in Rheumatoid Arthritis Patients is Associated With Elevated Anti-Cardiolipin Antibodies**
Israel/Italy
Y. Sherer, R. Gerli, R. Allegrucci, A. Giordano, B. Gilburd, G. Vaudo, S. Marchesi, G. Schillaci, E. Mannarino, Y. Shoenfeld
- [6] **Rapidly progressed mononeuritis multiplex in a case of central nervous system lupus associated with lupus anticoagulant.**
Japan
A. Goto, M. Mukai, A. Notoya, H. Takashima, T. Fukuda, M. Kaji, S. Kaieda, K. Tanaka, R. Ayukawa
- [7] **Antiphosphatidylethanolamine**
LA Kalashnikova, LA

- antibodies in patients with Sneddon's syndrome**
Russia
Dobrynina, EA
Aleksandrova, AA
Novikov, EL Nasonov,
EV Sergeeva, AL
Berkovskiy
- [8] **Antibodies to myelin basic protein, glial fibrillary acidic protein and neurospecific enolase in patients with primary antiphospholipid syndrome and nervous system involvement**
Russia
LA Kalashnikova, OI
Gurina, VP Chehonin, BD
Dzhamantaeva, LA
Dobrynina, EA
Aleksandrova, AA
Novikov
- [9] **Register of babies born to mothers with APS. First immunological results**
France/Slovenia/Italy
MH Aourousseau, E.
Lachassine, H. Dauphin,
O. Fain, M. Uzan, P. Le
Toumelin, S. Derenne, C.
Boinot, T. Avcin, M.
Motta, D. Faden, A.
Tincani, JC Piette, **MC Boffa**
- [10] **Evaluation Of Efficacy And Tolerability Of A Fixed Dose Combination Of Losartan And Ramipril In The Management Of Hypertensive Patients With Associated Diabetes Mellitus : Lord Trial (Losartan Ramipril in Diabetic Hypertensives)**
India
D. Pawar, S. Joshi, **M. Yeolekar**, K.Tripathi,
J.Giri, A. Maity, M
Chopda, S Maroli
- [11] **A Post Marketing Surveillance Of Telmisartan In Indian Hypertensive Patients**
India
D. Pawar, M. Yeolekar,
M. Chopda, S. Maroli, V.
Mourye
- [12] **HLA Associations Of Anti-Annexin V, Anti-Prothrombin, Anti-Beta2GPI, Anti-Protein C And Anti-Protein S Antibodies In Systemic Lupus Erythematosus**
Italy/Spain
M. Galeazzi, G. Morozzi,
GD Sebastiani, F.
Bellisai, R. Cervera, E. de
Ramon Garrido, A.
Fernandez Nebro, O. De
Pità

- [13] **The Relationship Of OXLDL, β 2GPI and β 2GPI-OXLDL Complexes In Patients With APS**
Slovenia
A. Ambrozic, **T. Kveder**,
B. Rozman, E. Matsuura
- [14] **High Levels Of Antibodies To CMV And To CMV-Peptide In Sera Of APS Patients.**
United States
K. Labat, M. Vega-Ostertag, **SS Pierangeli**,
AE Gharavi
- [15] **A Peptide Derived From Cytomegalovirus Reverses Thrombosis Induced By Antiphospholipid Antibodies.**
United States
M. Vega-Ostertag, X. Liu,
V. Henderson, AE
Gharavi, SS Pierangeli
- [16] **Upregulation of Expression Of IL-6 and IL-8 In Endothelial Cells By Antiphospholipid Antibodies.**
United States
M. Vega-Ostertag, M.
Lindsay, K. Labat, EN
Harris, SS Pierangeli
- [17] **Factor V Leiden (G1691A), prothrombin (G2021A) and 5,10-methylentetrahydrofolatereductase (C677T) gene mutations in patients with primary antiphospholipid syndrome (PAPS) and cerebrovascular disease**
Russia
LA Kalashnikova,
NL Patrusheva, LI
Patrushev, T. Kovalenko,
LA Dobrynina, EN
Aleksandrova, EL
Nassonov
- [18] **Differences in Myocardial Involvement in Primary Versus Secondary Antiphospholipid Syndrome**
Greece
I. Moyssakis, **NJ Pantazopoulos**, M.
Tektonidou, D.
Papadopoulos, E.
Gialafos, V. Votteas
- [19] **Right Ventricular Performance Index in Patients with Antiphospholipid Syndrome and Pulmonary Hypertension**
Greece
I. Moyssakis, **NJ Pantazopoulos**, E.
Gialafos, M. Tektonidou,
V. Vassiliou, V. Votteas
- [20] **Heart Lesions in Patients with Systemic Lupus Erythematosus. Influence of Antiphospholipid Antibodies.**
Greece
I. Moyssakis,
NJPantazopoulos, M.
Tektonidou, E. Gialafos,
P. Vlahoyannopoulos, V.
Votteas

- [21] **The condition of mucous stomach in systemic lupus erythematosus (SLE) patients and APS patients.**
Russia
TM Reshetnyak, IA Doroshkevich, AE Karateev, SG Radoneska-Lapovok, AV Novikova, LV Kondratieva, EL Nassonov
- [22] **Acute Respiratory Distress Syndrome In The Catastrophic Antiphospholipid Syndrome**
Spain/South Africa
S. Bucciarelli, **R. Cervera**, G.Espinosa, JA Gómez-Puerta, G. Claver, M. Ramos-Casals, M. Ingelmo, J. Font, RA Asherson
- [23] **Anti Phospholipid Antibody Syndrome Presenting As Retinal Vein Occlusion**
India
F. Manuel, G. Rajasekhar, LM Christina, S.Anandan, S. Premalatha, S. Shobana, V. Mahalakshmi, R. Sudha, M. Rashmi, S. Murugan, S. Adikrishnan
- [24] **Effect of anti beta2-glycoprotein I lupus anticoagulant antibodies on clotting time in the presence of human umbilical vein endothelial cells.**
Italy
A. Banzato, A. Biasiolo, A. Rosato. V. Pengo
- [25] **Thrombotic thrombocytopenic purpura in two patients with antiphospholipid syndrome**
Japan
Y. Kon, T. Atsumi, M. Kondo, Y. Sakai. S. Yasuda, Y. Amasaki, T. Koike
- [26] **OxLDL/b2GPI complexes in type II Diabetes Mellitus**
United States/Japan
LR Lopez, B. Hurley, J. Kuca, **K. Dier**, C. Fink, E. Matsuura
- [27] **Prevalence of Antiphospholipid Antibodies in a Lupus Inception Cohort: Brain Connections**
United States
RL Brey, SL Holliday, PA Padilla, N. Naqibuddin, M. Petri

- [28] **Long Term Follow-up of Patients with Phospholipid Antibodies** T. Loughran, C. Galea, S. Lakshminarayanan, **A. Parke**
United States
- [29] **Short Term Lack Of Efficacy Of Rituximab In A Thrombocytopaenic Patient With Primary Antiphospholipid Syndrome** C. Tommasino, G. Fossati, A. Saulino, A. Margarita, F. Ferrara, L. Iannaccone, V. Brancaccio, **PRJ Ames**
Italy/United Kingdom

TUESDAY 16 NOVEMBER 2004 Posters 8.00am to 5.30pm

- [1] **Enoxaparin In Pregnancy Loss Associated With Antiphospholipid Antibodies** **B Grand**, A. Ventura, D. Riveros
Argentina
- [2] **The role of annexin A5 in the antiphospholipid syndrome** **HB de Laat**, PhG de Groot, IJ Mackie, S. Schoormans, M. Adam, G. Purdy, B. Woodhams, RHWM Derksen, W. van Heerde
Netherlands/United Kingdom/France
- [3] **Pregnancy Outcomes in Women with Lupus Nephritis and Antiphospholipid Antibodies** **VD. Garovic**, D. Reed, M. Sitina, KG Moder
United States/Czech Republic
- [4] **Randomized controlled trial of aspirin and combined aspirin-heparin in antiphospholipid complicated pregnancy** **J. Witjaksono**, K. Tambunan
Indonesia
- [5] **Annexin V Antibodies and Their Role in Complications of Pregnancy** **L. Cooper**, A. Ochert, Y. Tayob, M. Parry, M.

- [6] **Low Protein Z Concentration In Women With Early Fetal Losses, A New Tool To Detect APS?**
Germany
- [7] **Health-Related Quality of Life and Prospective Treatment in Antiphospholipid Antibody Syndrome.**
United States
- [8] **Serum Anticardiolipin & Antiphospholipid Antibodies in patients with autoimmune disorders**
Iran
- [9] **Antiphospholipid and anti-annexin A5 antibodies in patients with recurrent IVF-ET failure and recurrent pregnancy loss**
Japan
- [10] **Absence of Antibodies to beta2 Glycoprotein1 In Multiple Sclerosis.**
Israel
- [11] **Antiphospholipid syndrome with neurological symptoms. Case report.**
Czech Republic
- [12] **Circulating oxLDL/ β 2GPI Complexes in Autoimmune Disease: Pathogenic Implications for Systemic Lupus Erythematosus and Systemic Sclerosis**
United States/Japan
- F. Bergmann**, WN Kühn-Velten, C. Nolte, G. Dubenhorst, S. Spranger, B. Kazmierczak
- GA McCarty**, TE Cason
- A. Naghi**, M. Shaiegan, Mahnaz Aghaiipour
- H. Matsubayashi**, M. Shida, A. Kondo, T. Sugi, T. Makino
- J. Chapman**, M. Blank, M. Gurevich, Y. Shoenfeld, A. Achiron
- D. Jilek**, V. Kral, J. Markova
- LR Lopez, **K. Dier**, B. Hurley, J. Kuca, C. Fink, E. Matsuura

- [13] **Antiphospholipid Syndrome Profile in Hepatitis C Viral Infected Patients with Compensated Liver** Egypt
AS Ellabban, ME Abd EL-Fattah, T. Motamed
- [14] **The induction of LAC by immunotherapy with biological response modifier in recurrent miscarriage patients** Japan
K. Katano, MS Ogasawara, K. Aoki, K. Suzumori
- [15] **Antiphospholipid antibodies as a baseline risk factor for damage development in Systemic Lupus Erythematosus.** Norway
A. Becker-Merok, OP Rekvig, **JC Nossent**
- [16] **Autoimmune hepatitis – a new manifestation of the Antiphospholipid antibody syndrome ?** Norway
A. Becker-Merok, **JC Nossent**
- [17] **Antiphospholipid Antibodies and Hormone Related Thrombosis** United States
AM Conti-Kelly, TP Greco Jr, **TP Greco**
- [18] **Lyme Disease vs. APS - You Guess!** United States
TP Greco Jr, AM Conti-Kelly, **TP Greco**
- [19] **Anti-Annexin V And Anti-Prothrombin Antibodies In Patients With Suspected Aps** Germany
F. Bergmann, G. Fredenhagen
- [20] **Antiphospholipid Syndrome Associated With Malignancies** Spain/South Africa
JA Gómez-Puerta, **R. Cervera**, G. Espinosa, G. Claver, S. Bucciarelli, M. Ramos-Casals, M. Ingelmo, RA Asherson, J. Font
- [21] **Clinical features of possible** **JK Kaburaki**, MK

- antiphospholipid syndrome (APS)**
Japan
- Kuwana, YI Ikeda
- [22] **Autoimmune Myelofibrosis in Systemic Lupus Erythematosus with the Antiphospholipid Antibody Syndrome**
United States
- SF Williams, HW Tun,
DM Menke, **KT Calamia**
- [23] **Circulating levels of tissue factor and proinflammatory cytokines in patients with primary APS or leprosy-related aPL**
Argentina
- RR Forastiero**, ME
Martinuzzo, G. de
Larrañaga
- [24] **Prospective Analysis of Antiphospholipid Antibodies in a Lupus Cohort**
United States
- M. Petri**
- [25] **No association of antiphospholipid antibody with premature atherosclerosis in premenopausal patients with systemic lupus erythematosus.**
South Korea
- CS Cho**, YJ Shin, CS
Park, WU Kim, SH Park
- [26] **Antiphospholipid syndrome nephropathy in systemic lupus nephritis: clinical, biological and histological analysis of 26 patients.**
France
- B. Vidal, **R. Cevallos**, D.
Nochy, G. Choukroun, P.
Duhaut, JP Ducroix
- [27] **Clinical and immunological manifestations of Japanese patients with antiphospholipid syndrome (APS): a cohort of 82 patients**
Japan
- Y. Sakai**, T. Atsumi, Y.
Kon, M. Bohgaki, S.
Yasuda, O. Amengual, Y.
Amasaki, T. Koike
- [28] **Platelet associated Tissue Factor expression in patients with antiphospholipid syndrome.**
Italy
- M. Frigerio, F. Rossi, F.
Veglia, **PL Meroni**, P.
Biglioli, E. Tremoli, M.
Camera
- [29] **Comparison of Prothrombin Versus Phosphatidylserine/Prothrombin Antigenic Substrates for the**
- K. Dier**, LR Lopez, CA
Fink

Detection of Antiprothrombin

Antibodies

United States

- [30] **Murine monoclonal antibodies to phospholipid binding proteins interfere with protein C system on platelet surface** A. Membré, **V. Regnault**, JP Max, D.Wahl, T. Lecompte
France

THURSDAY 18 NOVEMBER 2004 Posters 8.00am to 5.30pm

- [1] **Lupus Anticoagulant interferes with detection of heparin levels in plasma** **RT Urbanus**, PhG de Groot, RHWM Derksen
Netherlands
- [2] **Modeling and Refinement of Lupus Anticoagulant Testing via Neural Network Analysis** **JDL Nolen**, CA Sheppard, A. Duncan
United States
- [3] **Relation Between Lupus-Antiphospholipids And Lupus Heart Disorders** **AO Toure**, S. Diop, A. Kane, D.Thiam
Senegal
- [4] **Anti-cardiolipin antibody in suspected anti-phospholipid antibody syndrome The start of a prospective study** **TL de Malmanche**, A. Sturgess, W. Gallatley
Australia
- [5] **Monoclonal Antiphosphatidylserine Antibodies Prevent Invasion Of JAR Choriocarcinoma Through Matrigel Coated Filters.** **NS Rote**
United States
- [6] **The Amino-Terminal Heavy Chain Region of Factor 12 recognized by Anti-factor 12 Antibodies in Patients with Recurrent Pregnancy Losses** **AI Inomo**, TS Sugi, HM Matsubayashi, TM Makino

Japan

- [7] **Withdrawn**
- [8] **Prevalence and clinical significance of antiphospholipid antibodies in patients with thrombotic events who have no autoimmune disease** **M. Mukai**, M. Nozaki, M. Maekawa, Y. Takeda, H. Takashima, A. Notoya
Japan
- [9] **Antithrombotic treatments for asymptomatic APS in Japanese Patients** **J. Okada**, S. Suzuki, A. Ishikawa, H. Kondo
Japan
- [10] **A Re-evaluation Of The Normal Cut-off Assignment and Low Positive Values For Anticardiolipin IgM Tests.** R. Cashburn-Budd, V. Henderson, E. Harley, A. Bradwell, EN Harris, **SS Pierangeli**
United States/United Kingdom
- [11] **Anti-beta2-Glycoprotein Antibodies' Avidity** **S. Cucnik**, T. Kveder, I. Krizaj, B. Rozman, B. Bozic
Slovenia
- [12] **The Recognition of beta2GPI by Polyclonal Anti-beta2GPI Antibodies** **S. Cucnik**, T. Kveder, I. Krizaj, B. Rozman, B. Bozic
Slovenia
- [13] **Analytical Evaluation of New Anti-Phospholipid Antibodies (APA) Immunoassays with Monoclonal Antibody Calibration.** **B. Woodhams**, P. Chrisment, V. Quignon, Y. Malard, M. Grimaux, K. Rodolfo
France
- [14] **Analytical Evaluation of Two New Anti-Beta2Glycoprotein 1 Immunoassays Using Monoclonal Antibody Calibration.** **B. Woodhams**, P. Chrisment, V. Quignon, Y. Malard, M. Grimaux, K. Rodolfo
France

- [15] **Analytical evaluation of a New Anti-Prothrombin Immunoassay based on Monoclonal Antibody Calibration**
France
- [16] **The Overall Haemostatic Potential (OHP) identifies hypercoagulability in patients with antiphospholipid antibodies**
Australia
- [17] **Real World Experience With Antiphospholipid Antibodies (aPL): How Useful Is Anti-β2-Glycoprotein-I (β2GPI) Test?**
Netherlands/United States
- [18] **Real World Experience With aPL - Degree of Anticardiolipin Antibody (aCL) Variation Between Assays**
United States/Netherlands
- [19] **Influences of monoclonal antiphospholipid antibodies on the activities of coagulation factors**
Japan
- [20] **The value of IgM phosphatidylserine dependent antiprothrombin antibody determination for the diagnosis of antiphospholipid syndrome**
Japan
- [21] **Effect of Different Coating Concentrations on the Detection of Various Species of Anti-Phospholipid Antibodies.**
United States
- [22] **Poor sensitivity of the ASLA test for the detection of LA in women with obstetric complications**
Argentina
- B. Woodhams**, P. Chrisment, S. Le Floch, A. Guilloteau, M. Grimaux, K. Rodolfo
- J. Curnow**, M. Aboud, CM Ward, C. Roddie, M-C Morel-Kopp
- W. Derksen**, D. Erkan, V. Kaplan, L. Sammaritano, SS Pierangeli, R. Roubey, MD Lockshin
- D. Erkan**, B. Spicyn, M. Peterson, W. Derksen, L. Sammaritano, SS Pierangeli, MD Lockshin
- M. Ieko**, T. Atsumi, M. Takeda, S. Naito, T. Tarumi, T. Nakabayashi, T. Koike
- O. Amengual**, T. Atsumi, K. Yujiro, Y. Sakai, M. Bohgaki, S. Furukawa, S. Yasuda, Y. Amasaki, M. Ieko, T. Koike
- T. Prestigiacomo**, W. Tan, SR Binder
- YP Adamczuk, ML Iglesias Varela, G. Pombo, **RR Forastiero**, ME Martinuzzo

- [23] **Variability of Anticardiolipin and Anti-B2GP1 Antibodies in Patients with Antiphospholipid Antibodies with and without Antiphospholipid Syndrome**
Portugal
C. Favas, A. Grilo, J. Marques, **J. Delgado Alves**, M. Vaz Riscado
- [24] **Hydroxychloroquine effects on IgG and IgM anticardiolipin antibodies**
France
R. Cevallos, P. Duhaut, JP Ducroix
- [25] **A New Lupus Anticoagulant Test Based On Dilute Prothrombin Time**
United Kingdom/United States
IJ Mackie, AS Lawrie, RS Greenfield, ER Guinto, SJ Machin
- [26] **A Comparison Of Five Commercial Anti-beta2 Glycoprotein I Kits**
Australia
RJ Wilson, PG Landsberg, JC Neil, RL Prentice. A. Klestov
- [27] **IgG anti-oxLDL/b2GPI antibodies in the antiphospholipid syndrome: Association with arterial thrombosis**
United States/Japan
LR Lopez, **K. Dier**, J. Andrews, C. Fink, JT Merrill, E. Matsuura
- [28] **Autoantibodies against N-homocysteinylated albumin in patients with antiphospholipid syndrome: a preliminary report.**
Poland
J. Swadzba, A. Padjas, A. Undas, T. Iwaniec, J. Musia
- [29] **Anti-beta2-GPI antibodies recognize an epitope on domain I only after a phospholipid induced conformational change**
Netherlands
HB de Laat, M. van Lummel, RHWM Derksen, PhG de Groot
- [30] **Does Heparinase Treatment Of Plasma Affect The Detection Of Lupus Anticoagulants?**
United Kingdom
C. Brookfield, G. Jowitt, **K. Goodfellow**, S. Kitchen,